The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...

This amounts to one of the most significant federal government investments in the behavioral health sector in history. For ...

Asian American populations, particularly when broken down into ethnic groups, have allergy health outcomes that are distinct ...

The Biden administration’s final regulation affecting the Medicare Advantage industry would come with a much lighter touch ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Documents show Robert F. Kennedy Jr. invested in biotech companies and consulted on health care — interests he might have to ...

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...